I’m glad I’m not the only one thinking that way. FDA approval would be an incredible achievement and I want to be on board when it happens - if we get bad trial results then it’ll be a great buying opportunity in what will one way or another be a profit making company. As for worst case I was pretty surprised by the size for the drop in late 2018 after the (in my opinion) failed LVAD trial - but it’s recovered nicely for those who held on. I’d average down and have my fingers crossed again I guess!
Hopefully the FDA calendar works a little faster than MSB and the timelines pan out nicely with FDA approval first. And even more hopefully we get great P3 results.
Whatever happens 2020 will be an interesting year.
Ann: MSB Files GvHD Clinical Efficacy and Safety Data with US FDA, page-73
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.46 |
Change
-0.048(3.15%) |
Mkt cap ! $1.681B | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.50 | $1.45 | $6.766M | 4.615M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 11116 | $1.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 43258 | 20 |
View Market Depth
| Last trade - 15.23pm 08/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |